Depending on age, PS, organ function, etc. doxorubicin-based chemotherapy remains the standard of care systemic therapy option. A clinical trial exploring check-point inhibitor/s is a very reasonable choice given preliminary data. The hope/goal here would be to find an effective (neo)adjuvant option...